Zealand Pharma A/S

CPSE:ZEAL Stock Report

Market Cap: DKK 29.9b

Zealand Pharma Valuation

Is ZEAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZEAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DKK 181.38
Fair Value
134.0% overvalued intrinsic discount
16
Number of Analysts

Below Fair Value: Insufficient data to calculate ZEAL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZEAL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZEAL?

Key metric: As ZEAL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ZEAL. This is calculated by dividing ZEAL's market cap by their current earnings.
What is ZEAL's PE Ratio?
PE Ratio4.5x
EarningsDKK 6.68b
Market CapDKK 29.89b

Price to Earnings Ratio vs Peers

How does ZEAL's PE Ratio compare to its peers?

The above table shows the PE ratio for ZEAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.8x
BAVA Bavarian Nordic
10.3x-7.83%DKK 14.6b
GMAB Genmab
13x6.82%DKK 115.0b
KRYS Krystal Biotech
29.2x31.66%US$5.8b
TGTX TG Therapeutics
10.8x-2.35%US$5.0b
ZEAL Zealand Pharma
4.5x-77.75%DKK 29.9b

Price-To-Earnings vs Peers: ZEAL is good value based on its Price-To-Earnings Ratio (4.5x) compared to the peer average (15.9x).

Price to Earnings Ratio vs Industry

How does ZEAL's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ZEAL 4.5xIndustry Avg. 17.2xNo. of Companies6PE01632486480+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ZEAL is good value based on its Price-To-Earnings Ratio (4.5x) compared to the European Biotechs industry average (17.1x).

Price to Earnings Ratio vs Fair Ratio

What is ZEAL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZEAL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.5x
Fair PE Ratio7.1x

Price-To-Earnings vs Fair Ratio: ZEAL is good value based on its Price-To-Earnings Ratio (4.5x) compared to the estimated Fair Price-To-Earnings Ratio (7.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZEAL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 424.50
DKK 813.88
+91.73%
24.09%DKK 1,120.00DKK 430.00n/a16
Oct ’26DKK 495.00
DKK 813.88
+64.42%
24.09%DKK 1,120.00DKK 430.00n/a16
Sep ’26DKK 449.40
DKK 835.47
+85.91%
24.16%DKK 1,120.00DKK 400.00n/a15
Aug ’26DKK 327.50
DKK 849.50
+159.39%
22.39%DKK 1,120.00DKK 400.00n/a16
Jul ’26DKK 364.80
DKK 890.50
+144.11%
18.06%DKK 1,120.00DKK 485.00n/a14
Jun ’26DKK 453.50
DKK 903.69
+99.27%
19.06%DKK 1,120.00DKK 485.00n/a13
May ’26DKK 466.50
DKK 936.38
+100.73%
14.94%DKK 1,120.00DKK 730.00n/a13
Apr ’26DKK 465.80
DKK 955.92
+105.22%
15.59%DKK 1,150.00DKK 730.00n/a13
Mar ’26DKK 663.00
DKK 947.85
+42.96%
12.69%DKK 1,100.00DKK 730.00n/a13
Feb ’26DKK 735.50
DKK 1,007.64
+37.00%
9.36%DKK 1,100.00DKK 750.00n/a11
Jan ’26DKK 715.50
DKK 1,012.18
+41.46%
9.63%DKK 1,100.00DKK 750.00n/a11
Dec ’25DKK 730.00
DKK 1,015.00
+39.04%
10.37%DKK 1,100.00DKK 815.00n/a11
Nov ’25DKK 839.50
DKK 1,007.89
+20.06%
11.69%DKK 1,106.00DKK 800.00DKK 512.609
Oct ’25DKK 810.00
DKK 1,022.29
+26.21%
10.31%DKK 1,106.00DKK 800.00DKK 495.007
Sep ’25DKK 886.50
DKK 1,015.14
+14.51%
10.00%DKK 1,106.00DKK 800.00DKK 449.407
Aug ’25DKK 913.00
DKK 989.86
+8.42%
9.59%DKK 1,100.00DKK 800.00DKK 327.507
Jul ’25DKK 912.50
DKK 918.00
+0.60%
12.22%DKK 1,100.00DKK 800.00DKK 364.806
Jun ’25DKK 639.50
DKK 785.57
+22.84%
8.94%DKK 840.00DKK 625.00DKK 453.507
May ’25DKK 630.00
DKK 782.00
+24.13%
10.03%DKK 840.00DKK 600.00DKK 466.507
Apr ’25DKK 681.50
DKK 754.29
+10.68%
14.38%DKK 840.00DKK 570.00DKK 465.807
Mar ’25DKK 649.00
DKK 598.67
-7.76%
26.15%DKK 800.00DKK 382.00DKK 663.006
Feb ’25DKK 470.40
DKK 423.33
-10.01%
11.18%DKK 485.00DKK 355.00DKK 735.506
Jan ’25DKK 373.20
DKK 379.00
+1.55%
11.69%DKK 430.00DKK 295.00DKK 715.506
Dec ’24DKK 330.20
DKK 365.33
+10.64%
9.32%DKK 400.00DKK 295.00DKK 730.006
Nov ’24DKK 299.00
DKK 343.83
+14.99%
9.28%DKK 380.00DKK 295.00DKK 839.506
DKK 813.88
Fair Value
47.8% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/06 04:54
End of Day Share Price 2025/11/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 33 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yihan LiBarclays
Laura HindleyBerenberg
Kerry HolfordBerenberg